Clinical trial details

An Open-label, Multicenter, Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of RO7428731 in Participants With Glioblastoma Expressing Mutant Epidermal Growth Factor Receptor Variant III

Identifier

BP42573

Sponsor

ROCHE FARMA, S.A.

Principal Investigator

MARIA VIEITO VILLAR

Service

Oncology

Study details

Tumor type: GLIOMA
Stage: Early/Locally advanced, Advanced
Main Investigational Agent : Biespecific antibodies
Phase: I
Randomization: Non-randomized

Molecular details

Biomarker: EGFR pos
Biomarker criteria: Mandatory
Prescreening: Local/Central
Additional study population requirements: Participants must have confirmed EGFRvIII-expression

Drug details

Arm A: RO7428731

Links

Clinical Trials GOV (NCT identifier): NCT05187624
EU Clinical Trials Register (eudraCT Identifier): 2021-001197-37